2026: reflecting on the last year’s research progress and looking at what’s ahead
2025 was one of our most exciting years yet for Parkinson’s research. We saw the launch of EJS ACT-PD, the world’s largest clinical trial for Parkinson’s, the start of recruitment for the phase 3 trial of ambroxol, the forging of new strategic partnerships, and much...
Learn more
Parkinson’s therapies in the clinical trial pipeline: a 10-year retrospective analysis
A special edition of our annual clinical trial report has now been published in the Journal of Parkinson’s Disease (JPD), providing an overview of the Parkinson’s clinical trial landscape from 2015 to 2024. The report was produced by the Cure Parkinson’s research team in collaboration…
Cure Parkinson’s publishes commentary piece on combination therapies
As part of our updated research strategy, Cure Parkinson’s is committed to championing the development of combination therapies for Parkinson’s. To raise awareness of this in the Parkinson’s research community, members of our research team wrote an article which has now been published in the…
Meet the Researcher: Professor Huw Morris on developing the role of genetics in Parkinson’s clinical trials
In this series from Cure Parkinson’s, we hear directly from the scientists putting our funded research projects into action. From learning about their career journeys to getting an inside look at their studies, we’ll discover how their work aims to support people living with Parkinson’s. …
Cure Parkinson’s launches new evaluation panel for our combination therapies funding call
As part of our recent funding call for projects testing combination therapies, Cure Parkinson’s has put together a new expert panel to assess the applications and recommend the most promising projects for funding. What is the funding call about? One of the four pillars of…
DAPA-PD, the phase 2 clinical trial of dapansutrile, is now underway
We are excited to announce that the first participant on the Cure Parkinson’s and Van Andel Institute co-funded trial of dapansutrile, an anti-inflammatory drug, has now received either the treatment or placebo, marking the beginning of the trial. What is DAPA-PD? Dapansutrile for Parkinson’s (DAPA-PD)…